Celcuity Inc. Schedules Release of Second Quarter 2023 Financial Results and Webcast/Conference Call
03 August 2023 - 1:30PM
Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology
company focused on development of targeted therapies for oncology,
today announced that it will release its financial results for the
second quarter 2023 after the stock market close on Thursday,
August 10, 2023. Management will host a webcast/teleconference the
same day at 4:30 p.m. Eastern Time to discuss the results and
provide a corporate update.
Webcast and Conference Call
Information
To participate in the teleconference, domestic callers should
dial 1-888-886-7786 and international callers should dial
1-416-764-8658. A live webcast presentation can also be
accessed using this weblink:
https://viavid.webcasts.com/starthere.jsp?ei=1625068&tp_key=c09a941d3d.
A replay of the webcast will be available on the Celcuity website
following the live event.
About Celcuity
Celcuity is a clinical-stage biotechnology company focused on
development of targeted therapies for treatment of multiple solid
tumor indications. The company's lead therapeutic candidate is
gedatolisib, a potent, pan-PI3K and mTOR inhibitor. Its mechanism
of action and pharmacokinetic properties are highly differentiated
from other currently approved and investigational therapies that
target PI3K or mTOR alone or together. A Phase 3 clinical trial,
VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant
with or without palbociclib in patients with HR+/HER2- advanced
breast cancer is currently enrolling patients. More detailed
information about the VIKTORIA-1 study can be found at
ClinicalTrials.gov. The company's CELsignia companion diagnostic
platform is uniquely able to analyze live patient tumor cells to
identify new groups of cancer patients likely to benefit from
already approved targeted therapies. Further information about
Celcuity can be found at Celcuity.com. Follow us on LinkedIn and
Twitter.
Contacts:
Celcuity Inc. Brian Sullivan,
bsullivan@celcuity.com Vicky Hahne,
vhahne@celcuity.com (763) 392-0123
ICR Westwicke Robert Uhl, robert.uhl@westwicke.com
(619) 228-5886
Celcuity (NASDAQ:CELC)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Celcuity (NASDAQ:CELC)
Historical Stock Chart
Von Mai 2023 bis Mai 2024